Abstract
CardioVascular (CV) Disease (CVD) accounts for 25% of all UK deaths [1-4]. Before developing and applying new or existing CV risk prediction tools [5-22] for prediction of incident CVD events, it is important to have a description of the baseline characteristics of the patients who experienced a myocardial Infarction (MI) event. This paper presents the baseline characteristics of a cohort of patients who experienced a first MI between 1st of January 2006 and 31st of December 2014 in England, UK, age equal or greater than 35 years
Methods
It is used the Aurum database from the Clinical Practice Research Datalink (CPRD), which includes patients from primary care, linked with practice level Index of Multiple Deprivation (IMD) data to ascertain patients diagnosed for the first time in their lives with MI between 1st of January 2006 and 31st of December 2014 in England, UK, age equal or greater than 35 years. It is reported the baseline characteristics of this population: biological parameters, comorbidities and medications, at the time of the first MI event which took place within the considered time window. It is also reported age, gender, follow-up time (i.e. defined as duration from first MI until censoring defined as the earliest date of end of study 31st of December 2014, date of no survival, transferred out date and last collection date), time to no survival after first MI (i.e. defined as time from first MI until time of no survival taken place before the end of study of 31st of December 2014) and deprivation information.
Results
For the period of study of 1st of January 2006 to 31st of December 2014, a total of 101,407 patients met the inclusion criteria: 63,939 people were male patients (63%) and 37,468 were female patients (37%), age (mean ± standard deviation) at diagnosis was lower for male patients (66.81 ± 13.19) compared to female patients (74.83 ± 13.01). Within the above period of time of 9 years (i.e. 1st of January 2006 to 31st of December 2014), there were 14,192 who had a first MI and did not survive beyond the date of 31st of December 2014 because of cardiovascular reasons, or 14% of the cohort: from this subgroup (i.e. 14,192) more than 85% were older than 70 years old (i.e. 12,101). The MI follow-up in years (mean ± standard deviation) was 3.24 ± 2.52 years when using the end date of 31st of December 2014. Time to no survival after first MI was a little bit longer for male patients (3.83 ± 3.29) than for female patients (3.39 ± 3.09) when using the end date of 31st of December 2014: however, if the cohort of 101,407 patients would be followed for another 5 years beyond the above end date of 31st of December 2014 (i.e. 31st of December 2019), then the time to no survival after first MI would show a more clear distinction with 6.21 ± 3.87 for male patients and 5.20 ± 3.85 for female patients.
Patients were homogeneously distributed in terms of social deprivation (IMD quintiles): 20% quintile 1-least deprived, 20.4% quintile 2, 19.9% quintile 3, 19.6% quintile 4, 19.8% quintile 5-most deprived.
In terms of Body Mass Index (BMI), 1.5% was underweight, 21% normal weight, 28.5% overweight, 21% obese and 26% had a missing value.
The biological parameters consisted of: Diastolic Blood Pressure (mean ± standard deviation) which was 78.55 ± 11.27 mm Hg for male patients and 78.22 ± 11.69 for female patients, Systolic Blood Pressure was 127.97 ± 16.31 mm Hg for male patients and 131.98 ± 17.84 mm Hg for female patients, Plasma cholesterol was 4.33 ± 1.07 mmol/L for female patients and 3.84 ± 0.99 mmol/L for male patients, Plasma triglyceride was 1.50 ±0.99 mmol/L for male patients and 1.45±0.91 mmol/L for female patients, and High Density Lipoprotein (HDL)-cholesterol was 1.15 ± 0.33 mmol/L for male patients and 1.43 ± 0.38 mmol/L for female patients.
For comorbidities: 10.62% of the cohort had a record of stroke or transient ischemic attack, 6.91% heart failure, 41.33% hypertension, 19.27% chronic kidney disease, 31.87% coronary heart disease, 19.20% diabetes, 20.68% hyperlipidemia, 36.40% family history of CVD, 11.66% cardiovascular procedures, 13.24% chronic pulmonary disease, 9.53% atrial fibrillation, 1.11% heart valve disease, 6.74% peripheral vascular disease, 0.45% pericardial disease, 7.91% hypothyroidism, 17.41% angina, 3.23% rheumatoid arthritis, 0.54% cardiomyopathy. In terms of medications: 48.09% of the cohort were treated with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB), 50.01% lipid-regulating drugs (statins), 15.56% alpha-blockers, 7.11% anticoagulants, 49.11% antiplatelets, 42.62% beta-blockers, 40.11% calcium-channel-blockers, 16.81% diabetes mellitus treatment, 28.88% antianginal, 46.08% diuretics and 71.28% any antihypertensives including centrally-acting (e.g. Methoserpidine), Vasodilators or combined (e.g. beta/thiazide/potassium).
Conclusions
This paper identified the baseline characteristics (biological, comorbidities, medication and deprivation) of an MI cohort in England, UK between 2006 and 2014 and based on the CPRD Aurum database. From the comorbidities the highest was hypertension, while for the medications was the antihypertensives. It was also noticed that male patients tend to survive a little bit more (3.83 ± 3.29) than female patients (3.39 ± 3.09) after a first MI within the considered time window of 9 years (i.e. 1st of January 2006 to 31st of December 2014), or 6.21 ± 3.87 for male patients and 5.20 ± 3.85 for female patients if considering a longer period of time of 14 years (i.e. 1st of January 2006 to 31st of December 2019). Fig 1 shows also the entire MI cohort (i.e. 101,407 patients) by age groups: 946 patients for lower than 40 years old, 7656 patients for 40 to 49 age interval, 16526 patients for 50 to 59 age interval, 22678 patients for 60 to 69 age interval and 53601 patients equal or above 70 years old.
Distribution of MI patients by age groups: 946 patients < 40 age, 7656 patients for 40 to 49 age interval, 16526 patients for 50 to 59, 22678 patients for 60 to 69, 53601 patients for equal or above 70 years old.
Data Availability
Data is not available.
Details of ethics approval
This study is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Copyright ©[2024], re-used with the permission of The Health & Social Care Information Centre. All rights reserved. The study protocol was approved by the CPRD’s Independent Scientific Advisory Committee (protocol number 20_177). Generic ethical approval for observational research using CPRD with approval from ISAC has been granted by a Health Research Authority (HRA) Research Ethics Committee (East Midlands—Derby, REC reference number 05/MRE04/87).
Competing interests
The author declares no competing interests.
Acknowledgment
The author would like to thank to the Heart Research UK – Translation Research Project Grants for supporting this work. The author would like to thank to Dr Salwa Zghebi and Prof Mamas Mamas for the medical and the pharmacological inputs, and also to Prof. Evangelos Kontopantelis and Dr Rosa Parisi for their support.
Footnotes
↵* Abstract shown initially in the Health Services Research (HSR) UK conference 2021.
References
